Alnylam Pharmaceuticals | ALNY - Des Atouts

Prix De L'Action
321.18
Variation Quotidienne
-6.07 -1.85%
Mensuellement
-0.37%
Annuel
41.94%
Q2 Prévisions
309.25




Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Moderna USD 12.34B 203M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 126.81B 25.48B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Takeda JPY 15.41T 938.47B 2025-12
Tectonic Therapeutic USD 261.04M 15.96M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12
Xencor USD 875.5M 6.68M 2025-12